BHCM
XERS icon

Brevan Howard Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Brevan Howard Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Buy
23,543
+7,790
+49% +$49.7K ﹤0.01% 1918
2026
Q1 		$91.4K Sell
15,753
-76,663
-83% -$508K ﹤0.01% 2043
2025
Q4 		$725K Sell
92,416
-39,744
-30% -$313K 0.01% 916
2025
Q3 		$1.08M Sell
132,160
-72,864
-36% -$484K ﹤0.01% 866
2025
Q2 		$957K Buy
205,024
+12,748
+7% +$58.4K 0.01% 1083
2025
Q1 		$1.06M Buy
+192,276
New +$776K 0.01% 479

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brevan Howard Capital Management's XERS Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Xeris Biopharma Holdings (XERS) stake by 49% in Q2 2026, buying an estimated $49.7K and bringing the position to 23,543 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #1918.

Brevan Howard Capital Management first reported a position in XERS in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.08M in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Brevan Howard Capital Management held 23,543 shares of Xeris Biopharma Holdings worth $186K as of Q2 2026.
  • Brevan Howard Capital Management bought 7,790 Xeris Biopharma Holdings shares in Q2 2026, an estimated $49.7K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1918 holding.
  • Brevan Howard Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2025 and has held it in 6 quarters since.
  • Brevan Howard Capital Management's Xeris Biopharma Holdings position peaked at $1.08M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.